Forteza (benzydamine hydrochloride) oral spray 0.15% 30 ml. vial №1

Description

Forteza 30 ml Storage
active substance: benzydamine hydrochloride;

15 ml of solution contain 22.5 mg of benzydamine hydrochloride;

Excipients: saccharin sodium, ethanol 96%, methylparaben (E 218), glycerin, polysorbate 20, peppermint essence, quinoline yellow (E 104), patented blue V (E 131), purified water.

Forteza 30 ml Dosage form
Oral solution.

Main physical and chemical properties: green clear liquid with mint smell.

Forteza 30 ml Pharmacotherapeutic group
Tools for use in dentistry. Other means for topical application in the oral cavity.

ATX code A01A D02.

Pharmacological properties

Pharmacodynamics.

Benzidamine is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and anti-exudative properties.

In clinical trials, benzydamine has been shown to be effective in relieving the symptoms that accompany localized irritant pathological processes in the mouth and pharynx.

In addition, when applied topically, benzydamine acts as a disinfectant that has a local anesthetic effect on the oral mucosa.

Pharmacokinetics.

The effectiveness of benzydamine when applied topically is due to the ability to penetrate the epithelial layer and achieve effective concentrations in inflamed tissues.

When applied topically at this concentration, benzydamine is absorbed by the mucous membrane, but its concentration in blood plasma is so low that it can not have any pharmacological action.

Benzidamine is excreted mainly in the urine as inactive metabolites or conjugation products.

Indication
Symptomatic treatment:

pain caused by gingivitis, stomatitis, pharyngitis;
irritation and inflammation of the oropharynx;
in dentistry after tooth extraction or for prophylactic purposes.
Contraindication
Hypersensitivity to the active substance or to any other components of the drug.

Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed.

Features of application
In case of sensitivity with long-term use, treatment should be discontinued and a physician should be consulted to prescribe appropriate treatment.

In some patients, ulcers of the mucous membrane of the cheeks / pharynx can be caused by serious pathological processes. Therefore, patients whose symptoms have worsened or decreased within 3 days or who have a fever or other symptoms should consult a physician or dentist as appropriate.

Benzidamine is not recommended in patients with hypersensitivity to acetylsalicylic acid or other NSAIDs.

Use of the drug may cause bronchospasm in patients with bronchial asthma or a history of bronchial asthma. Such patients must be warned.